Benefits
No published evidence that it prevents infections
The often quoted claim of 23% fewer respiratory illness episodes comes from a 12-week study that has never been published in a searchable medical journal, so its methods, participants and statistics cannot be checked by anyone outside the company. It is supplier material rather than verifiable evidence. Reducing infections would also be a disease-prevention claim, which a dietary supplement is not permitted to make. No published trial has tested whether this combination changes how often people get sick.
Symptom severity claim is unverified
The '30% less severe symptoms' figure comes from that same unpublished 12-week study, so the number of participants, the methods and the statistics behind it are not available for review. Treat it as marketing material, not evidence. The one published trial did not measure illness or symptoms at all.
Humoral immunity — IgG increase
In the single published trial, 40 healthy adults aged 35 to 60 took 500 mg a day or placebo for 28 days. IgG rose about 22% more in the supplement group than in the placebo group (p=0.04), and about 27% above their own starting level. This was a small four-week study that measured a blood marker, not whether anyone stayed well. IgG is the most abundant antibody class, the primary long-term protective antibody against pathogens. Increased IgG suggests enhanced humoral immune response, the remembered/antibody arm of immunity.
Cell-mediated immunity: T cell markers rose above placebo
In the published 28-day trial, total T cells rose about 9%, CD4+ T cells about 10% and the CD4+/CD8+ ratio about 17% above each person's starting value, and all three were also significantly higher than placebo (p=0.03, p=0.03 and p=0.009). This is one 28-day study in 40 healthy adults, and it measured blood markers only. T cells are central to cell-mediated immunity, the arm that responds to unfamiliar pathogens. What a short-term shift in these blood measures means for the everyday health of a healthy adult is not known.
IFN-γ increase (innate immunity)
In the same 28-day trial in 40 adults, serum IFN-γ (interferon-gamma) rose about 14% more in the supplement group than in the placebo group (p=0.02). IFN-γ is a key cytokine for antiviral defense and immune cell activation, bridging innate and adaptive immunity. Five of the six blood measures were higher than placebo, but the natural killer cell difference was not (p=0.17), so the innate arm is the weakest part of the picture. No published study links these short-term blood markers to fewer or milder infections in people taking this product.
Quality of life claims come from unpublished data
The '23% better quality of life' and '2x improvement in psychological well-being' figures come from the same unpublished 12-week study and cannot be checked against any published paper. The one published trial did not measure quality of life or psychological well-being at all; it reported that participants rated their own immune-related complaints lower than the placebo group did on a questionnaire.
Format note: this is not a health benefit
The supplier describes this ingredient as mild tasting and 70 to 80% water soluble, which is why it appears in drinks and gummies as well as capsules. That is a convenience for product manufacturers, not a health effect, and it says nothing about whether the ingredient works.
Mechanism of action
Ashwagandha adaptogenic + immune modulation
Ashwagandha is a herb studied mainly for stress and sleep, with some laboratory work on immune signalling. Compounds in it called withanolides are proposed to influence T cell and natural killer cell activity. This explanation is borrowed from ashwagandha research in general: the one published trial of this specific combination did not measure stress, and it did not show a placebo-controlled change in T cells or natural killer cells.
Haritaki polyphenol immune support
Haritaki (Terminalia chebula) contains polyphenols such as gallic acid and ellagic acid. These show antioxidant and immune-signalling activity mostly in laboratory studies. The idea that they complement ashwagandha's withanolides is a theory, since no published human study has compared the two plants separately against the combination.
Three pillars of immune defense
The 'three pillars' framing comes from the supplier. In the published 28-day trial, interferon-gamma, IgG, total T cells, CD4+ cells and the CD4/CD8 ratio were all higher than placebo, but the natural killer cell difference versus placebo was not significant (p=0.17), so the innate arm is the weakest part of the picture. These are blood measures in 40 healthy adults over four weeks, and no published study links them to fewer or milder infections in people taking this product.
Synergistic botanical combination
The Ashwagandha + Haritaki combination was identified through systematic testing of 40 immune-supportive plants — the supplier says the chosen ratio works better than either plant on its own. That head to head comparison has not been published, so the synergy claim rests on company data. A patent describes an invention; it is not evidence that a product works.
Stress-mediated immune support
Ashwagandha's well-characterized stress modulation effects indirectly support immune function — chronic stress is one of the primary drivers of impaired immune response. This is a plausible link rather than a demonstrated one here: the published trial of this combination did not measure stress, mood or well-being, so any effect on those remains unproven for this product.
Clinical trials
A 12-week study described only in the supplier's marketing materials. Searching the medical literature for this ingredient, its research code and the plant combination turns up no such study, so its design, statistics and full results cannot be examined by anyone outside the company.
Reported by the supplier as 120 healthy adults, but not independently verifiable because the study is unpublished.
The company reports 23% fewer respiratory infections, 30% less severe symptoms, 23% better quality of life scores and a doubling of psychological well-being. None of these numbers appear in any published paper, and none are accompanied by participant details or statistics that others can check. Claims about preventing infections are disease-prevention claims that a dietary supplement may not make, so these figures should not be relied on when choosing a product.
A 28-day randomized, double-blind, placebo-controlled pilot trial of the standardized Terminalia chebula plus Withania somnifera combination at 500 mg a day versus placebo, published in Food and Nutrition Research in 2024. Participants were healthy adults aged 35 to 60 who felt their immunity was low. It measured blood markers only, not illness. The paper's funding statement is inconsistent: it declares no industry funding while the manufacturer's sponsorship is acknowledged elsewhere.
40 healthy men and women aged 35 to 60 who felt their immunity was low. 28-day intervention. Small pilot study.
Compared with placebo: interferon-gamma about 14% higher (p=0.02), IgG about 22% higher (p=0.04), total T cells (p=0.03), CD4+ cells (p=0.03), the CD4/CD8 ratio (p=0.009), and self-rated immune complaint scores about 69% lower (p=0.0002). The natural killer cell rise of about 20% was measured against baseline and was NOT significant versus placebo (p=0.17). No infection, illness or symptom outcomes were measured, and the study ran 28 days in 40 people.
An animal study in which the immune system was deliberately suppressed, used by the developers to choose a ratio of the two plants before testing in people. Animal results do not show what a supplement does in humans, and this work does not appear among the published records for this combination.
Not applicable — preclinical experimental immunosuppression model.
The combination was reported to support immune measures in the animal model. These are findings in animals with an artificially suppressed immune system, which is not the same as a healthy person taking a capsule, and the report is not publicly available for review.